Pardes Biosciences, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Thomas G. Wiggans
- Full Time Employees
- 57
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2173 Salk Avenue Carlsbad CA United States of America 92008
- IPO Date
- Dec 27, 2021
- CIK
- 0001822711
- Website
- pardesbio.com
- Similar Companies
- Business
- Pardes Biosciences, Inc. (PRDS), a clinical-stage biopharmaceutical company founded in 2020 and headquartered in Carlsbad, California, discovers, develops, and commercializes novel oral antiviral therapeutics targeting viral diseases, primarily leveraging structure-based drug design and reversible-covalent chemistry; its lead product candidate, pomotrelvir (formerly PBI-0451), comprises a direct-acting inhibitor of the main protease (Mpro) essential for replication of SARS-CoV-2 and other pathogenic coronaviruses, with additional early-stage research assets including next-generation Mpro inhibitors exhibiting broad-spectrum pan-coronavirus activity. The company operates as a subsidiary of MediPacific, Inc., following MediPacific's completion of its acquisition on August 31, 2023, for approximately $2.13 per share in cash plus a contingent value right tied to potential future monetization of its COVID-19 antiviral portfolio and intellectual property, a transaction driven by Foresite Capital Management after pomotrelvir's Phase 2 trial in April 2023 failed to meet its primary endpoint of viral clearance in mild-to-moderate COVID-19 patients and prompted suspension of further clinical development.
Pardes Biosciences Announces Closing of Tender Offer
MediPacific Offering $2.13 Per Share Plus One Contingent Value Right Per Share in Tender Offer for Pardes Biosciences
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
MediPacific Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Pardes Biosciences Shares
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
PARDES BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pardes Biosciences, Inc. - PRDS
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
PARDES BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pardes Biosciences, Inc. - PRDS
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm